Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 85

1.

AC-186, a selective nonsteroidal estrogen receptor β agonist, shows gender specific neuroprotection in a Parkinson's disease rat model.

McFarland K, Price DL, Davis CN, Ma JN, Bonhaus DW, Burstein ES, Olsson R.

ACS Chem Neurosci. 2013 Sep 18;4(9):1249-55. doi: 10.1021/cn400132u. Epub 2013 Aug 6.

2.

Pimavanserin, a 5-HT2A receptor inverse agonist, reverses psychosis-like behaviors in a rodent model of Alzheimer's disease.

Price DL, Bonhaus DW, McFarland K.

Behav Pharmacol. 2012 Aug;23(4):426-33. doi: 10.1097/FBP.0b013e3283566082.

PMID:
22750845
3.

Discovery of potential antipsychotic agents possessing pro-cognitive properties.

Lameh J, McFarland K, Ohlsson J, Ek F, Piu F, Burstein ES, Tabatabaei A, Olsson R, Bradley SR, Bonhaus DW.

Naunyn Schmiedebergs Arch Pharmacol. 2012 Mar;385(3):313-23. doi: 10.1007/s00210-011-0702-2. Epub 2011 Nov 15.

PMID:
22083558
4.

Pimavanserin, a 5-HT2A inverse agonist, reverses psychosis-like behaviors in a rodent model of Parkinson's disease.

McFarland K, Price DL, Bonhaus DW.

Behav Pharmacol. 2011 Oct;22(7):681-92. doi: 10.1097/FBP.0b013e32834aff98.

PMID:
21921840
5.

Differential regulation of muscarinic M1 receptors by orthosteric and allosteric ligands.

Davis CN, Bradley SR, Schiffer HH, Friberg M, Koch K, Tolf BR, Bonhaus DW, Lameh J.

BMC Pharmacol. 2009 Dec 2;9:14. doi: 10.1186/1471-2210-9-14.

6.

AC-260584, an orally bioavailable M(1) muscarinic receptor allosteric agonist, improves cognitive performance in an animal model.

Bradley SR, Lameh J, Ohrmund L, Son T, Bajpai A, Nguyen D, Friberg M, Burstein ES, Spalding TA, Ott TR, Schiffer HH, Tabatabaei A, McFarland K, Davis RE, Bonhaus DW.

Neuropharmacology. 2010 Feb;58(2):365-73. doi: 10.1016/j.neuropharm.2009.10.003. Epub 2009 Oct 14.

PMID:
19835892
8.

Pharmacology of N-desmethylclozapine.

Lameh J, Burstein ES, Taylor E, Weiner DM, Vanover KE, Bonhaus DW.

Pharmacol Ther. 2007 Aug;115(2):223-31. Epub 2007 May 21. Review.

PMID:
17583355
9.

ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models.

Gardell LR, Vanover KE, Pounds L, Johnson RW, Barido R, Anderson GT, Veinbergs I, Dyssegaard A, Brunmark P, Tabatabaei A, Davis RE, Brann MR, Hacksell U, Bonhaus DW.

J Pharmacol Exp Ther. 2007 Aug;322(2):862-70. Epub 2007 May 22.

10.

Effects of cannabinoid receptor ligands on psychosis-relevant behavior models in the rat.

Martin RS, Secchi RL, Sung E, Lemaire M, Bonhaus DW, Hedley LR, Lowe DA.

Psychopharmacology (Berl). 2003 Jan;165(2):128-35. Epub 2002 Oct 29.

PMID:
12404071
11.

Pharmacological comparison of a recombinant CB1 cannabinoid receptor with its G(alpha 16) fusion product.

Martin RS, Reynen PH, Calixto JJ, Reyes CL, Chang TK, Dietrich PS, Bonhaus DW, MacLennan SJ.

J Biomol Screen. 2002 Jun;7(3):281-9.

PMID:
12097191
12.

High-affinity interactions of ligands at recombinant guinea pig 5HT7 receptors.

Wilcox RE, Ragan JE, Pearlman RS, Brusniak MY, Eglen RM, Bonhaus DW, Tenner TE Jr, Miller JD.

J Comput Aided Mol Des. 2001 Oct;15(10):883-909.

PMID:
11918075
13.

The 5-HT3 subtype of serotonin receptor contributes to nociceptive processing via a novel subset of myelinated and unmyelinated nociceptors.

Zeitz KP, Guy N, Malmberg AB, Dirajlal S, Martin WJ, Sun L, Bonhaus DW, Stucky CL, Julius D, Basbaum AI.

J Neurosci. 2002 Feb 1;22(3):1010-9.

14.

Allosteric modulation of [(3)H]gabapentin binding by ruthenium red.

Taylor MT, Bonhaus DW.

Neuropharmacology. 2000 Apr 27;39(7):1267-73.

PMID:
10760368
15.

RS-127445: a selective, high affinity, orally bioavailable 5-HT2B receptor antagonist.

Bonhaus DW, Flippin LA, Greenhouse RJ, Jaime S, Rocha C, Dawson M, Van Natta K, Chang LK, Pulido-Rios T, Webber A, Leung E, Eglen RM, Martin GR.

Br J Pharmacol. 1999 Jul;127(5):1075-82.

16.

Absorption and brain penetration of a high affinity, highly selective 5-HT2C receptor antagonist, RS-102221.

Bonhaus DW, Rocha CL, Dawson MW, Eglen RM.

Ann N Y Acad Sci. 1998 Dec 15;861:269. No abstract available.

PMID:
9928284
18.

Evidence for inverse agonism of SR141716A at human recombinant cannabinoid CB1 and CB2 receptors.

MacLennan SJ, Reynen PH, Kwan J, Bonhaus DW.

Br J Pharmacol. 1998 Jun;124(4):619-22.

19.

Ligand efficacy and potency at recombinant alpha2 adrenergic receptors: agonist-mediated [35S]GTPgammaS binding.

Jasper JR, Lesnick JD, Chang LK, Yamanishi SS, Chang TK, Hsu SA, Daunt DA, Bonhaus DW, Eglen RM.

Biochem Pharmacol. 1998 Apr 1;55(7):1035-43.

PMID:
9605427
20.

Enhanced delayed matching performance in younger and older macaques administered the 5-HT4 receptor agonist, RS 17017.

Terry AV Jr, Buccafusco JJ, Jackson WJ, Prendergast MA, Fontana DJ, Wong EH, Bonhaus DW, Weller P, Eglen RM.

Psychopharmacology (Berl). 1998 Feb;135(4):407-15.

PMID:
9539266
21.

Pharmacological characterization of N-methyl-D-aspartate receptors in spinal cord of rats with a chronic peripheral mononeuropathy.

Wei HB, Jakeman LB, Hunter JC, Bonhaus DW.

Neuropharmacology. 1997 Nov-Dec;36(11-12):1561-9.

PMID:
9517427
22.

Catecholamine modulatory effects of nepicastat (RS-25560-197), a novel, potent and selective inhibitor of dopamine-beta-hydroxylase.

Stanley WC, Li B, Bonhaus DW, Johnson LG, Lee K, Porter S, Walker K, Martinez G, Eglen RM, Whiting RL, Hegde SS.

Br J Pharmacol. 1997 Aug;121(8):1803-9.

23.

[3H]RS 57639, a high affinity, selective 5-HT4 receptor partial agonist, specifically labels guinea-pig striatal and rat cloned (5-HT4S and 5-HT4L) receptors.

Bonhaus DW, Berger J, Adham N, Branchek TA, Hsu SA, Loury DN, Leung E, Wong EH, Clark RD, Eglen RM.

Neuropharmacology. 1997 Apr-May;36(4-5):671-9.

PMID:
9225293
24.

RS-102221: a novel high affinity and selective, 5-HT2C receptor antagonist.

Bonhaus DW, Weinhardt KK, Taylor M, DeSouza A, McNeeley PM, Szczepanski K, Fontana DJ, Trinh J, Rocha CL, Dawson MW, Flippin LA, Eglen RM.

Neuropharmacology. 1997 Apr-May;36(4-5):621-9.

PMID:
9225287
25.

Comparison of 5-HT4 receptors in guinea-pig colon and rat oesophagus: effects of novel agonists and antagonists.

Leung E, Pulido-Rios MT, Bonhaus DW, Pekins LA, Zeitung KD, Hsu SA, Clark RD, Wong EH, Eglen RM.

Naunyn Schmiedebergs Arch Pharmacol. 1996 Jul;354(2):145-56.

PMID:
8857591
26.

The beta 1 sodium channel subunit modifies the interactions of neurotoxins and local anesthetics with the rat brain IIA alpha sodium channel in isolated membranes but not in intact cells.

Bonhaus DW, Herman RC, Brown CM, Cao Z, Chang LF, Loury DN, Sze P, Zhang L, Hunter JC.

Neuropharmacology. 1996 May;35(5):605-13.

PMID:
8887969
27.

RS-17053 (N-[2-(2-cyclopropylmethoxyphenoxy)ethyl]-5-chloro-alpha, alpha-dimethyl-1H-indole-3-ethanamine hydrochloride), a selective alpha 1A-adrenoceptor antagonist, displays low affinity for functional alpha 1-adrenoceptors in human prostate: implications for adrenoceptor classification.

Ford AP, Arredondo NF, Blue DR Jr, Bonhaus DW, Jasper J, Kava MS, Lesnick J, Pfister JR, Shieh IA, Vimont RL, Williams TJ, McNeal JE, Stamey TA, Clarke DE.

Mol Pharmacol. 1996 Feb;49(2):209-15.

PMID:
8632751
28.

Characterization of [3H]GR 113808 binding to 5-HT4 receptors in brain tissues from patients with neurodegenerative disorders.

Wong EH, Reynolds GP, Bonhaus DW, Hsu S, Eglen RM.

Behav Brain Res. 1996;73(1-2):249-52.

PMID:
8788512
29.

Pharmacological evaluation of 1229U91, a novel high-affinity and selective neuropeptide Y-Y1 receptor antagonist.

Hegde SS, Bonhaus DW, Stanley W, Eglen RM, Moy TM, Loeb M, Shetty SG, DeSouza A, Krstenansky J.

J Pharmacol Exp Ther. 1995 Dec;275(3):1261-6.

PMID:
8531090
30.

Pharmacological characterization of two novel and potent 5-HT4 receptor agonists, RS 67333 and RS 67506, in vitro and in vivo.

Eglen RM, Bonhaus DW, Johnson LG, Leung E, Clark RD.

Br J Pharmacol. 1995 Aug;115(8):1387-92.

31.

Allosteric interactions among agonists and antagonists at 5-hydroxytryptamine3 receptors.

Bonhaus DW, Stefanich E, Loury DN, Hsu SA, Eglen RM, Wong EH.

J Neurochem. 1995 Jul;65(1):104-10.

PMID:
7790853
32.

RS 39604: a potent, selective and orally active 5-HT4 receptor antagonist.

Hegde SS, Bonhaus DW, Johnson LG, Leung E, Clark RD, Eglen RM.

Br J Pharmacol. 1995 Jul;115(6):1087-95.

33.

The pharmacology and distribution of human 5-hydroxytryptamine2B (5-HT2B) receptor gene products: comparison with 5-HT2A and 5-HT2C receptors.

Bonhaus DW, Bach C, DeSouza A, Salazar FH, Matsuoka BD, Zuppan P, Chan HW, Eglen RM.

Br J Pharmacol. 1995 Jun;115(4):622-8.

34.

Functional evidence equating the pharmacologically-defined alpha 1A- and cloned alpha 1C-adrenoceptor: studies in the isolated perfused kidney of rat.

Blue DR Jr, Bonhaus DW, Ford AP, Pfister JR, Sharif NA, Shieh IA, Vimont RL, Williams TJ, Clarke DE.

Br J Pharmacol. 1995 May;115(2):283-94.

35.

Characterization and distribution of putative 5-ht7 receptors in guinea-pig brain.

To ZP, Bonhaus DW, Eglen RM, Jakeman LB.

Br J Pharmacol. 1995 May;115(1):107-16.

36.

Characterization of the electrophysiological, biochemical and behavioral actions of epibatidine.

Bonhaus DW, Bley KR, Broka CA, Fontana DJ, Leung E, Lewis R, Shieh A, Wong EH.

J Pharmacol Exp Ther. 1995 Mar;272(3):1199-203.

PMID:
7891333
37.

The interaction of RS 25259-197, a potent and selective antagonist, with 5-HT3 receptors, in vitro.

Wong EH, Clark R, Leung E, Loury D, Bonhaus DW, Jakeman L, Parnes H, Whiting RL, Eglen RM.

Br J Pharmacol. 1995 Feb;114(4):851-9.

38.

The identification of heterogeneity of 5-HT3 receptors with [3H]RS-42358-197.

Wong EH, Bonhaus DW, Eglen RM.

Adv Exp Med Biol. 1995;363:97-108. No abstract available.

PMID:
7618534
39.

[3H]RS-23597-190, a potent 5-hydroxytryptamine4 antagonist labels sigma-1 but not sigma-2 binding sites in guinea pig brain.

Bonhaus DW, Loury DN, Jakeman LB, Hsu SA, To ZP, Leung E, Zeitung KD, Eglen RM, Wong EH.

J Pharmacol Exp Ther. 1994 Oct;271(1):484-93.

PMID:
7965749
40.
41.

Cloning and expression of a 5-hydroxytryptamine7 receptor positively coupled to adenylyl cyclase.

Tsou AP, Kosaka A, Bach C, Zuppan P, Yee C, Tom L, Alvarez R, Ramsey S, Bonhaus DW, Stefanich E, et al.

J Neurochem. 1994 Aug;63(2):456-64.

PMID:
7518496
42.

Kindling induces the long-lasting expression of a novel population of NMDA receptors in hippocampal region CA3.

Kraus JE, Yeh GC, Bonhaus DW, Nadler JV, McNamara JO.

J Neurosci. 1994 Jul;14(7):4196-205.

43.

(R) and (S) RS 56532: mixed 5-HT3 and 5-HT4 receptor ligands with opposing enantiomeric selectivity.

Eglen RM, Bonhaus DW, Clark RD, Johnson LG, Lee CH, Leung E, Smith WL, Wong EH, Whiting RL.

Neuropharmacology. 1994 Mar-Apr;33(3-4):515-26.

PMID:
7984291
44.

[3H]BIMU-1, a 5-hydroxytryptamine3 receptor ligand in NG-108 cells, selectively labels sigma-2 binding sites in guinea pig hippocampus.

Bonhaus DW, Loury DN, Jakeman LB, To Z, DeSouza A, Eglen RM, Wong EH.

J Pharmacol Exp Ther. 1993 Nov;267(2):961-70.

PMID:
8246171
46.

2-(Quinuclidin-3-yl)pyrido[4,3-b]indol-1-ones and isoquinolin-1-ones. Potent conformationally restricted 5-HT3 receptor antagonists.

Clark RD, Miller AB, Berger J, Repke DB, Weinhardt KK, Kowalczyk BA, Eglen RM, Bonhaus DW, Lee CH, Michel AD, et al.

J Med Chem. 1993 Sep 3;36(18):2645-57.

PMID:
8410977
47.

Different densities of 5-HT3 receptors are labeled by [3H]quipazine, [3H]GR 65630 and [3H]granisetron.

Wong EH, Bonhaus DW, Lee JA, Wu I, Loury DN, Eglen RM.

Neuropharmacology. 1993 Sep;32(9):869-75.

PMID:
8232790
48.

RS 23597-190: a potent and selective 5-HT4 receptor antagonist.

Eglen RM, Bley K, Bonhaus DW, Clark RD, Hegde SS, Johnson LG, Leung E, Wong EH.

Br J Pharmacol. 1993 Sep;110(1):119-26.

49.

Labelling of 5-hydroxytryptamine3 receptors with a novel 5-HT3 receptor ligand, [3H]RS-42358-197.

Wong EH, Bonhaus DW, Wu I, Stefanich E, Eglen RM.

J Neurochem. 1993 Mar;60(3):921-30.

PMID:
8436978
50.

Uncompetitive antagonist binding: a biochemical index of activation of the NMDA receptor-coupled ion channel.

Bonhaus DW, McNamara JO.

Epilepsy Res Suppl. 1992;8:181-8. No abstract available.

PMID:
1384539

Supplemental Content

Loading ...
Support Center